Venue: The Fuqua School of Business, Duke University, 1 Towerview Drive, Durham, NC 27708-0120
Presentation
Competition in an Era of Stratified Medicines
The goal of stratified medicine is improve the practice of medicine by matching therapies to patient sub-populations through the use of clinical biomarkers, where the latter are broadly defined as any information showing a reliable, predictive correlation to differential patient responses. In this paper I consider economic and strategic issues that emerge with stratified medicine, such as implications for clinical trial design and implementation, patient recruitment strategies, challenges developing both the therapy and qualifying the diagnostic biomarker, intellectual property and pricing issues brought about by possible double marginalization, and pricing premia the market is willing to pay for stratified medicines. Finally, I will consider how these cost and pricing considerations will affect the nature of competition.